Published on 28 Feb 2023 on Zacks via Yahoo Finance
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 90.32%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.34 per share when it actually produced a loss of $0.28, delivering a surprise of 17.65%.